A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for advanced HCC.

Trial Details

NCT ID
NCT06294548
Phase
PHASE1 / PHASE2
Sponsor
University of Alabama at Birmingham
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Valemetostat
  • Atezolizumab
  • Bevacizumab
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249

Key Eligibility Criteria

  • Subjects must meet all the following criteria to be eligible for enrollment into the study:
  • Sign and date the informed consent form (ICF), prior to the start of any study-specific qualification procedures.
  • Subjects ≥18 years of age or the minimum legal adult age (whichever is greater) at the time the ICF is signed
  • HCC diagnosis confirmed by histology/cytology or clinically by American Association for Study of Liver Diseases (AASLD) 36 criteria in cirrhotic pa…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →